Injectable Resin Composite Versus Dual-cured Resin Cement for Cementation of Indirect Onlay Resto… (NCT05954156) | Clinical Trial Compass
CompletedNot Applicable
Injectable Resin Composite Versus Dual-cured Resin Cement for Cementation of Indirect Onlay Restorations
Egypt28 participantsStarted 2023-08-01
Plain-language summary
Marginal integrity is considered the main essential part of indirect restorations and any discrepancy after cementation and poor marginal fit can lead to microleakage, marginal discoloration, dissolution of cement and secondary caries. The type of cement used plays an important role and can govern the amount of augmentation in discrepancy after cementation.
Although resin cement is still the gold standard luting agent for the cementation of all indirect restoration, it lacks some properties that may be available in the restorative resin composite such as higher filler loading, higher mechanical properties and wear resistance.
may have been the first to propose the use of restorative, flowable resin composite as a luting agent for ceramic inlays. These authors demonstrated that with respect to polymerization rate, there were no advantages of dual curing-resin compared to light curing only. In addition, the overall handling of the light-curing flowable restorative resin composite was judged to be easier than that of the dual cured material. The same conclusions were drawn by Kramer and franken Berger who added that less luting resin composite overhangs were found with the light polymerized composite-resin because the clinician has more time for excess removal prior to polymerization. The claimed further potential advantages of using restorative rein composite as a luting agent is their resistance to wear which proved to be superior to resin cements
Who can participate
Age range
22 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with vital, asymptomatic, badly broken-down lower molar exhibiting at least two missing walls and one or more weakened or absent cusps (indicated for an onlay restoration), classified as ICDAS score (5)
* Patients with at least 20 teeth under occlusion.
* Age: 20-40 years.
* Males or females.
* Co-operative patients approving to participate in the trial.
* Good oral hygiene measures
* Teeth with no signs of pulpal involvement; healthy periodontal status; favorable occlusion
* Those in good general health.
Exclusion Criteria:
* Teeth with signs and symptoms of irreversible pulpitis or pulp necrosis or periapical pathosis
* Teeth supporting removable prostheses, or orthodontic appliances.
* Candidates with parafunction or bruxism or temporomandibular joint disorders
* Candidates with systemic diseases or disabilities that may affect participation.
* Heavy smoking.
* Pregnancy.
* Lack of compliance.
* Severe or active periodontal disease
* Non-vital or endodontically treated teeth
* Xerostomia
* Drug addiction; or any condition that could compromise study compliance.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinical Performance
Timeframe: 18 months change from baseline to 6, 12, and 18 months